Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
Amyloid Fibrils03:03

Amyloid Fibrils

9.2K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Context Memory Discrimination and Recognition in Humans: Development of a Novel Cognitive Task.

JMIR formative research·2026
Same author

A Scalable Touchscreen-Based Spatial Working Memory Task for Cross-Species Research.

bioRxiv : the preprint server for biology·2026
Same author

Attentional Deficits Do Not Explain Age-Related Impairments on the Mnemonic Similarity Task.

Hippocampus·2026
Same author

Multistep inference across the human lifespan can be improved with individualized memory interventions.

The journals of gerontology. Series B, Psychological sciences and social sciences·2026
Same author

Harmonized Protocol for Segmentation of the Hippocampal Tail on High-Resolution <i>in vivo</i> MRI from the Hippocampal Subfields Group (HSG).

bioRxiv : the preprint server for biology·2025
Same author

Advanced diffusion imaging in grey matter reflects individual differences in cognitive ability in older adults.

Imaging neuroscience (Cambridge, Mass.)·2025

Related Experiment Video

Updated: Jun 3, 2025

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

14.8K

APOE4 Increases Susceptibility to Amyloid, Accelerating Episodic Memory Decline.

Casey R Vanderlip1, Craig E L Stark1

  • 1Department of Neurobiology and Behavior, University of California Irvine.

Biorxiv : the Preprint Server for Biology
|January 7, 2025
PubMed
Summary

The strongest Alzheimer's disease (AD) genetic risk factor, Apolipoprotein E4 (APOE4), accelerates episodic memory decline. This decline is linked to amyloid duration and is dose-dependent, highlighting APOE4's specific impact on memory.

More Related Videos

Visualizing Axonal Growth Cone Collapse and Early Amyloid &#946; Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

7.9K
Preparation of Oligomeric &#946;-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.2K

Related Experiment Videos

Last Updated: Jun 3, 2025

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

14.8K
Visualizing Axonal Growth Cone Collapse and Early Amyloid &#946; Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

7.9K
Preparation of Oligomeric &#946;-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.2K

Area of Science:

  • Neurogenetics
  • Cognitive Neuroscience
  • Alzheimer's Disease Research

Background:

  • Apolipoprotein E4 (APOE4) is the primary genetic risk factor for sporadic Alzheimer's disease (AD).
  • APOE4 carriers exhibit increased amyloid-beta (Aβ) deposition and faster cognitive decline, especially in episodic memory.
  • The mechanisms behind APOE4's domain-specific cognitive vulnerability remain largely unknown.

Purpose of the Study:

  • To investigate whether accelerated episodic memory decline in APOE4 carriers is driven by Aβ deposition or heightened susceptibility to Aβ effects.
  • To analyze the relationship between amyloid duration and cognitive trajectories in individuals with different APOE genotypes.
  • To determine if APOE4's impact on cognitive decline is specific to episodic memory.

Main Methods:

  • Utilized data from the Alzheimer's Disease Research Initiative (ADRI).
  • Modeled amyloid duration (estimated years of amyloid positivity) and its association with cognitive performance.
  • Compared cognitive trajectories across APOE genotypes (noncarriers, heterozygotes, homozygotes) for various cognitive domains.

Main Results:

  • APOE4 carriers showed a significantly faster decline in episodic memory as a function of amyloid duration.
  • The episodic memory decline was dose-dependent, with APOE4 homozygotes experiencing more rapid decline than heterozygotes.
  • This accelerated decline was specific to episodic memory and not observed in other cognitive domains like processing speed or executive function.

Conclusions:

  • APOE4 genotype significantly influences cognitive trajectories in Alzheimer's disease, specifically accelerating episodic memory decline.
  • The findings suggest heightened susceptibility to Aβ-related hippocampal dysfunction in APOE4 carriers early in the disease.
  • Further research is warranted to explore distinct pathological cascades underlying these genotype-specific cognitive differences.